{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:23:35Z","timestamp":1788387815112,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Global Oncology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Real-world evidence on non-Hodgkin lymphoma (NHL) management in Latin America is currently lacking. The objective of this study was to describe treatment characteristics and outcomes of NHL in Latin America. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> A total of 2,967 patients with NHL with aggressive and indolent subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), and mucosa-associated lymphoid tissue (MALT) lymphoma, with incident or prevalent diagnosis between 2006 and 2015, were retrospectively identified using clinical charts registered in the Hemato-Oncology Latin America Observational Registry. Associations between treatment regimen and age at diagnosis with clinical outcomes within each subtype were estimated using Cox proportional hazard regression. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Most patients with NHL received 1L chemoimmunotherapy, most commonly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with\/without rituximab. Five-year survival rates were higher for MALT lymphoma (90.8%) and FL (87.6%) versus DLBCL (69.0%) and MCL (57.1%), with variations between countries. The median overall survival from first relapse for patients with DLBCL was 6.6 years, with lower risk of death for those diagnosed at age &lt; 65 years (hazard ratio = 0.732; P = .0161). Patients achieved a longer median progression-free survival with 1L rituximab-CHOP (R-CHOP) versus CHOP or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) (7.7 v 3.0 or 1.8 years, respectively). Use of regimens other than R-CHOP was associated with a higher risk of death\/progression for patients with DLBCL (rituximab, ifosfamide, carboplatin, and etoposide\/ifosfamide, carboplatin, and etoposide) and FL (CHOP). There was no relationship between treatment prescribed and age at diagnosis with outcomes from first\/second relapse in DLBCL and FL. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Differences in treatment outcomes between NHL subtypes were observed, reflecting variations in NHL management and barriers to treatment access in Latin America. These data provide necessary evidence to understand NHL management in this region and highlight the need to improve treatment outcomes for these patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/go.21.00265","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T20:00:51Z","timestamp":1651262451000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study"],"prefix":"10.1200","author":[{"given":"Miguel","family":"Pavlovsky","sequence":"first","affiliation":[{"name":"Servicio de Hematolog\u00eda e Investigaci\u00f3n Cl\u00ednica, Fundaci\u00f3n para Combatir la Leucemia (FUNDALEU), Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-2605","authenticated-orcid":false,"given":"Daniel","family":"Cubero","sequence":"additional","affiliation":[{"name":"CEPHO\/ABC School of Medicine, Santo Andr\u00e9, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys Patricia","family":"Agreda-V\u00e1squez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Enrico","sequence":"additional","affiliation":[{"name":"Hospital Italiano La Plata, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-5798","authenticated-orcid":false,"given":"Maria J.","family":"Mela-Osorio","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda e Investigaci\u00f3n Cl\u00ednica, Fundaci\u00f3n para Combatir la Leucemia (FUNDALEU), Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Armenta","family":"San Sebasti\u00e1n","sequence":"additional","affiliation":[{"name":"Centro Oncol\u00f3gico Estatal ISSEMYM, Toluca, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fogliatto","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9185-7434","authenticated-orcid":false,"given":"Roberto","family":"Ovilla","sequence":"additional","affiliation":[{"name":"Hospital Angeles Lomas, Huixquilucan, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-0928","authenticated-orcid":false,"given":"Oscar","family":"Avendano","sequence":"additional","affiliation":[{"name":"Medical Solutions S.A. Guatemala City, Guatemala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-605X","authenticated-orcid":false,"given":"Gerardo","family":"Machnicki","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Farmac\u00eautica Ltda, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Barreyro","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Farmac\u00eautica Ltda, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7322-7482","authenticated-orcid":false,"given":"Damila","family":"Trufelli","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Farmac\u00eautica Ltda, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-3477","authenticated-orcid":false,"given":"Pamella","family":"Villanova","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Farmac\u00eautica Ltda, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aogh.2014.09.009"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.05.008"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057617"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0939-7"},{"key":"b5","volume-title":"Cancer Incidence in Five Continents, Vol. XI. IARC Scientific Publication No. 166. Lyon: International Agency for Research on Cancer","author":"Bray F"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5578.5578"},{"key":"b7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"Tietsche De Moraes Hungria V","year":"2019","journal-title":"JCO Glob Oncol"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16124"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177204"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14122.1"},{"issue":"2","key":"b12","first-page":"94","volume":"73","author":"C\u00f3rdova-Ram\u00edrez AC","year":"2021","journal-title":"Rev Invest Clin"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21330"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28659"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1622"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.08.019"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70048-2"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO.21.00265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:05:50Z","timestamp":1653822350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO.21.00265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1200\/GO.21.00265"],"URL":"https:\/\/doi.org\/10.1200\/go.21.00265","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"2021-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2100265"}}